enGene Therapeutics Inc. Debt Securities, Available-for-sale, Amortized Cost
enGene Therapeutics Inc. (ENGN) had Debt Securities, Available-for-sale, Amortized Cost of $281.99 million as of 2026-04-30, per its 10-Q filed 2026-06-15.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-09-08
- 2026-04-30: Debt Securities, Available-for-sale, Amortized Cost $281.99M.
- 2026-01-31: Debt Securities, Available-for-sale, Amortized Cost $291.09M.
- 2025-10-31: Debt Securities, Available-for-sale, Amortized Cost $185.49M.
- 2025-07-31: Debt Securities, Available-for-sale, Amortized Cost $208.32M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-04-30 | $281.99M 10-Q · filed 2026-06-15 | |
| 2026-01-31 | $291.09M 10-Q · filed 2026-03-09 | |
| 2025-10-31 | $185.49M 10-Q · filed 2026-09-08 | |
| 2025-07-31 | $208.32M 10-Q · filed 2025-09-11 | |
| 2025-04-30 | $229.30M 10-Q · filed 2025-06-12 | |
| 2025-01-31 | $256.82K 10-Q · filed 2025-03-10 | |
| 2024-10-31 | $229.57M 10-K · filed 2025-12-22 | $229.57K 10-K · filed 2024-12-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |